Dr. Robert Gniadecki speaks with JCMS Editor-in-chief, Dr. Kirk Barber, about the article Gniadecki co-authored in the Sept/Oct 2019 edition of the Journal of Cutaneous Medicine and Surgery. They discuss two progressive primary cutaneous T-cell lymphomas for which there are no curative treatments, Mycosis fungoides and Sézary syndrome. Dr Gniadecki explains why Immunotherapy seems to be a promising avenue to achieve long-term disease control in CTCL, with compelling evidence indicating that Mycosis fungoides and Sézary syndrome are immunogenic lymphomas, which can be recognized by the patient’s immune system. They also discuss how current genomic techniques, such as estimating the mutational load by whole genome sequencing and neoantigen calling, are likely to provide clinically useful information facilitating personalized immunotherapy of CTCL. Dr. Robert Gniadecki is a professor of dermatology at the University of Alberta in Edmonton, where he is the director of the division of Dermatology and leads the Multidisciplinary Cutaneous Lymphoma Clinic.Theme music by Lee RosevereProduced by David McGuffin, Explore Podcast Productions, Ottawa